Shared burden

Having learned their lesson with PD-L1, companies are collaborating on assay standards for tumor mutation burden -- a likely contender for the next major biomarker in immuno-oncology. A Friends of Cancer Research-led consortium of pharmas and diagnostics companies is driving the charge and plans to publish a white paper with its recommendations this year.

The coalition has been gathering members and momentum since it began meeting in September to create a framework for comparing tests on tumor mutation burden (TMB). ...